Clinical management of bacterial vaginosis (BV) is difficult owing to inaccurate diagnostic tests, limited drug choices, and a high rate of recurrence. To our knowledge, there has not been a previous study of antimicrobial resistance (AMR) genes in community practice using next-generation sequencing (NGS). A case–control study (1 : 1 age-matched with and without BV) was undertaken in a series of 326 nongravid women of reproductive age with symptoms of BV to determine the prevalence of AMR genes. NGS was used to describe the complete vaginal microbiota and identify bacterial genes associated with resistance to: macrolides and/or lincosamides – ermA, ermB, ermC, erM, ermTR and mefA; tetracyclines, β-lactams, streptomycin, gentamicin and/or tobramycin – acrA, acrB, mecA, tet, tetA, tolC and aac2; 5-nitroimadazoles – nim and nimB; and triazoles – cdr1 and mdr1. An evidence base was created to inform treatment decisions applicable to individual patients. AMR genes were identified in all drug classes: macrolides, 35.2 %; lincosamides, 35.6 %; tetracyclines, 21.8 %; aminoglycosides (streptomycin, gentamicin and tobramycin), 5.2 % each; 5-nitroimidazoles, 0.3 %; and triazoles, 18.7 %. There was more than a fourfold-higher frequency of AMR genes in pathogens from BV than from non-BV patients for macrolides (58.2 versus 12.3 %, respectively), lincosamides (58.9 versus 12.3 %) and tetracyclines (35.6 versus 8.0 %) (Fisher's exact test; all p < 0.001). For each patient with BV, the spectrum of resistance genes was matched to the pathogens present. AMR genes were present in the majority of vaginal microbiomes of patients with symptoms of BV.
BorisJ.,
PåhlsonC.,
LarssonP. G.1997; Six years observation after successful treatment of bacterial vaginosis. Infect Dis Obstet Gynecol 5:297–302 [View Article][PubMed]
BostwickD. G.,
WoodyJ.,
BuddW. T.2016; Next-generation sequencing of bacterial vaginosis: case : control study with comprehensive species-level description.
BoyanovaL.,
KolarovR.,
GergovaG.,
DimitrovaL.,
MitovI.2010; Trends in antibiotic resistance in Prevotella species from patients of the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in 2003–2009. Anaerobe 16:489–492 [View Article][PubMed]
BuddW. T.,
HarwichM.,
BostwickD. G.,
MeyersG.,
DiltsJ.,
O'HanlonK.,
WoodyJ.,
MasonL.,
ReynoldsT.2015; Metagenomics analysis using next generation sequencing of vaginal samples from community practices in the U.S. MOJ Cell Sci Rep 2:(2))
CardR. M.,
WarburtonP. J.,
MacLarenN.,
MullanyP.,
AllanE.,
AnjumM. F.2014; Application of microarray and functional-based screening methods for the detection of antimicrobial resistance genes in the microbiomes of healthy humans. PLoS One 9:e86428 [View Article][PubMed]
ChakravortyS.,
LeeJ. S.,
ChoE. J.,
RohS. S.,
SmithL. E.,
LeeJ.,
KimC. T.,
ViaL. E.,
ChoS. N.,
other authors.
2015; Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43–51 [View Article][PubMed]
De BackerE.,
DubreuilL.,
BraumanM.,
AcarJ.,
VaneechoutteM.2010; In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect 16:470–472 [View Article][PubMed]
DelgadoS.,
FlórezA. B.,
MayoB.2005; Antibiotic susceptibility of Lactobacillus and
Bifidobacterium species from the human gastrointestinal tract. Curr Microbiol 50:202–207 [View Article][PubMed]
ElkinsC. A.,
MullisL. B.2004; Bile-mediated aminoglycoside sensitivity in Lactobacillus species likely results from increased membrane permeability attributable to cholic acid. Appl Environ Microbiol 70:7200–7209 [View Article][PubMed]
EnneV. I.,
DelsolA. A.,
RoeJ. M.,
BennettP. M.2006; Evidence of antibiotic resistance gene silencing in Escherichia coli
. Antimicrob Agents Chemother 50:3003–3010 [View Article][PubMed]
FerrisM. J.,
MasztalA.,
AldridgeK. E.,
FortenberryJ. D.,
FidelP. L.Jr.,
MartinD. H.2004; Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 4:5 [View Article][PubMed]
FettweisJ. M.,
SerranoM. G.,
ShethN. U.,
MayerC. M.,
GlascockA. L.,
BrooksJ. P.,
JeffersonK. K.,
BuckG. A.,
Vaginal Microbiome Consortium.
2012; Species-level classification of the vaginal microbiome. BMC Genomics 13:(Suppl. 8)S17[PubMed]
FinegoldS. M.1996; Anaerobic Gram-negative bacilli. In Medical Microbiology, 4th edn. ch. 20 Edited by
BaronS.
Galveston, TX: University of Texas Medical Branch at Galveston;
FredricksD. N.,
FiedlerT. L.,
ThomasK. K.,
MitchellC. M.,
MarrazzoJ. M.2009; Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol 47:721–726 [View Article][PubMed]
GadG. F.,
Abdel-HamidA. M.,
FaragZ. S.2014; Antibiotic resistance in lactic acid bacteria isolated from some pharmaceutical and dairy products. Braz J Microbiol 45:25–33 [View Article][PubMed]
GuidoM.,
QuattrocchiM.,
ZizzaA.,
PasanisiG.,
PavoneV.,
LobreglioG.,
GabuttiG.,
De DonnoA.2012; Molecular approaches in the diagnosis of sepsis in neutropenic patients with haematological malignances. J Prev Med Hyg 53:104–108[PubMed]
HarwichM. D.Jr,
AlvesJ. M.,
BuckG. A.,
StraussJ.F.,III,
PattersonJ. L.,
OkiA. T.,
GirerdP. H.,
JeffersonK. K.2010; Drawing the line between commensal and pathogenic Gardnerella vaginalis through genome analysis and virulence studies. BMC Genomics 11:375 [View Article][PubMed]
HarwichM. D.Jr,
SerranoM. G.,
FettweisJ. M.,
AlvesJ. M.,
ReimersM. A.,
BuckG. A.,
JeffersonK. K.,
Vaginal Microbiome Consortium.
2012; Genomic sequence analysis and characterization of Sneathia amnii sp. nov. BMC Genomics 13:(Suppl. 8)S4 [View Article][PubMed]
KharsanyA. B.,
HoosenA. A.,
Van den EndeJ.1993; Antimicrobial susceptibilities of Gardnerella vaginalis
. Antimicrob Agents Chemother 37:2733–2735 [View Article][PubMed]
LeitschD.,
SókiJ.,
KolarichD.,
UrbánE.,
NagyE.2014; A study on Nim expression in Bacteroides fragilis
. Microbiology 160:616–622 [View Article][PubMed]
LöfmarkS.,
EdlundC.,
NordC. E.2010; Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50:(Suppl. 1)S16–S23 [View Article][PubMed]
MarrazzoJ. M.,
ThomasK. K.,
FiedlerT. L.,
RingwoodK.,
FredricksD. N.2008; Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med 149:20–28 [View Article][PubMed]
MitchellC.,
ManhartL. E.,
ThomasK.,
FiedlerT.,
FredricksD. N.,
MarrazzoJ.2012; Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study. Infect Dis Obstet Gynecol 2012:706540 [View Article][PubMed]
OlenderA.2013; Antibiotic resistance and detection of the most common mechanism of resistance (MLSB) of opportunistic Corynebacterium
. Chemotherapy 59:294–306 [View Article][PubMed]
ParmaM.,
Stella VanniV.,
BertiniM.,
CandianiM.2014; Probiotics in the prevention of recurrences of bacterial vaginosis. Altern Ther Health Med 20:(Suppl. 1)52–57[PubMed]
PiotP.,
van DyckE.,
GoodfellowM.,
FalkowS.1980; A taxonomic study of Gardnerella vaginalis (Haemophilus vaginalis) Gardner and Dukes 1955. J Gen Microbiol 119:373–396[PubMed]
RobicsekA.,
StrahilevitzJ.,
JacobyG. A.,
MacielagM.,
AbbanatD.,
ParkC. H.,
BushK.,
HooperD. C.2006; Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 12:83–88 [View Article][PubMed]
SalminenM. K.,
RautelinH.,
TynkkynenS.,
PoussaT.,
SaxelinM.,
ValtonenV.,
JärvinenA.2004; Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 38:62–69 [View Article][PubMed]
SchwebkeJ. R.,
DesmondR. A.2007; A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 44:213–219 [View Article][PubMed]
SobelJ. D.,
SchmittC.,
MeriwetherC.1993; Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis 167:783–784 [View Article][PubMed]
SrinivasanS.,
HoffmanN. G.,
MorganM. T.,
MatsenF. A.,
FiedlerT. L.,
HallR. W.,
RossF. J.,
McCoyC. O.,
BumgarnerR.,
other authors.
2012; Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One 7:e37818 [View Article][PubMed]
SwidsinskiA.,
Loening-BauckeV.,
SwidsinskiS.,
VerstraelenH.2015; Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch Gynecol Obstet 291:605–609[PubMed][CrossRef]
TomusiakA.,
StrusM.,
HeczkoP. B.2011; [Antibiotic resistance of Gardnerella vaginalis isolated from cases of bacterial vaginosis]. Ginekol Pol 82:900–904 (in Polish)[PubMed]
TuiteN.,
ReddingtonK.,
BarryT.,
ZumlaA.,
EnneV.2014; Rapid nucleic acid diagnostics for the detection of antimicrobial resistance in Gram-negative bacteria: is it time for a paradigm shift?. J Antimicrob Chemother 69:1729–1733 [View Article][PubMed]